Analysis conducted on glycan structure from sheep prion strains
Using liquid chromatography/mass spectrometry, researchers have revealed no major differences in glycan structures in two prion strains.
List view / Grid view
Using liquid chromatography/mass spectrometry, researchers have revealed no major differences in glycan structures in two prion strains.
Researchers have developed a new mass spectrometer that uses rotation frequencies of ionised molecules to measure mass with high accuracy.
The effect of various ion pairing reagents (amines and acidic counterions) on the LC/UV and LC/MS analysis of oligonucleotides (ONs) has been studied.
A new subspace mass spectrometry imaging method has enabled researchers to provide data sets exponentially faster.
Therapeutic oligonucleotides represent a recent breakthrough in the pharmaceutical industry.
Therapeutic oligonucleotides represent a recent breakthrough in the pharmaceutical industry. However, characterisation of oligos, specifically by ion-pair reversed phase liquid chromatography (IPRPLC), can be quite challenging.
Therapeutic oligonucleotides represent a recent breakthrough in the pharmaceutical industry.
Silencing RNA, or siRNA, are short, double-stranded RNA molecules which are not only an important research tool in molecular biology, but also an emerging therapeutic modality.
Superficially porous particle technologies provide a reduced diffusion path in comparison with their fully porous counterparts minimising the resistance to mass transfer during chromatographic separation.
1 July 2020 | By Phenomenex
In this on-demand webinar, we provide an overview of nucleic acid therapeutics and discuss the chromatographic challenges associated with oligonucleotides. We also explore modulation of the mobile phase additives alkylamine ion pair and perfluorinated alcohols. Finally, we will show how optimisation of mobile phase can improve not only chromatographic performance…
Learn how method development software helped Janssen Pharmaceuticals reduce method development time by 80% with a 25-fold increase in method quality
Track the emergence and fate of impurities throughout drug development, attach all the relevant analytical data, and store searchable knowledge.
26 June 2020 | By Tecan
This webinar described the recent efforts to identify small molecule therapeutics for the treatment of SARS-CoV-2 infection and COVID-19 disease.
Learn why measuring binding affinity is key to helping you decide the next steps in your research and what technologies are available to measure it.
A result is only as good as the sample preparation that preceded it.